Cibc World Market Inc. bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 19,960 shares of the biopharmaceutical company's stock, valued at approximately $1,205,000.
A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Xenon Pharmaceuticals during the second quarter valued at about $454,057,000. Holocene Advisors LP bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter worth approximately $56,637,000. Wellington Management Group LLP lifted its position in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company's stock worth $144,936,000 after acquiring an additional 1,435,096 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Xenon Pharmaceuticals by 1,968.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company's stock worth $38,650,000 after purchasing an additional 820,608 shares in the last quarter. Finally, Vestal Point Capital LP grew its holdings in shares of Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $62,600,000 after purchasing an additional 700,000 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Xenon Pharmaceuticals
In other news, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director directly owned 1,455 shares of the company's stock, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven Gannon sold 10,000 shares of Xenon Pharmaceuticals stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total value of $640,600.00. Following the transaction, the director owned 1,870 shares in the company, valued at approximately $119,792.20. This represents a 84.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,512 shares of company stock valued at $774,088 over the last three months. 2.91% of the stock is currently owned by corporate insiders.
Xenon Pharmaceuticals Stock Down 2.9%
Shares of XENE opened at $61.93 on Friday. The company has a 50-day moving average price of $63.04 and a two-hundred day moving average price of $56.36. The stock has a market cap of $5.99 billion, a price-to-earnings ratio of -13.07 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period last year, the business earned ($1.07) EPS. Equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently issued reports on XENE shares. Royal Bank Of Canada lowered their price objective on Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating on the stock in a research report on Friday, August 7th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. JPMorgan Chase & Co. lifted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 27th. Needham & Company LLC lowered their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $77.13.
Get Our Latest Research Report on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Read More
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
